Doximity vs Omnicell
Doximity (DOCS) and Omnicell (OMCL) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $5.12B
- Last close
- $28.73
- 12 months
- −38.1%
- Market value
- $1.5B
- Last close
- $32.51
- 12 months
- −5.3%
At a glance
- The biggest part of Doximity's revenue is Subscription (94%); at Omnicell it is Connected devices, software licenses, and other (48%).
- By market value, Doximity ($5.1B) is about 3.4 times Omnicell ($1.5B).
- Over the last 12 months Doximity's share price moved −38.1% and Omnicell's −5.3%; against the S&P 500 that is −43.8 points and −11.0 points.
- In their last fiscal years Doximity kept 30.4% of revenue as net income and Omnicell 0.2%.
- In the last 90 days insiders reported 0 open-market purchases at Doximity and 0 at Omnicell; members of Congress disclosed 0 trades in Doximity and 0 in Omnicell.
- Next results: Doximity Feb 3, 2027, Omnicell Feb 3, 2027.
How each one makes money: Doximity revenue · Omnicell revenue
Share prices on one chart
Doximity and Omnicell, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Doximity DOCSNYSE · Health Care Technology | Omnicell OMCLNASDAQ · Health Care Technology | |
|---|---|---|
| Size and profitability | ||
| Market value | $5.12B | $1.5B |
| Revenue, last fiscal year | $645M | $1.18B |
| Net income, last fiscal year | $196M | $2.05M |
| Net marginNet income as a share of revenue | 30.4% | 0.2% |
| Free cash flow | $326M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Common questions
How is Doximity different from Omnicell?
Doximity (DOCS) is in Health Care Technology on NYSE, with $645M of revenue in its last fiscal year and a net margin of 30.4%. Omnicell (OMCL) is in Health Care Technology on NASDAQ, with $1.18B of revenue in its last fiscal year and a net margin of 0.2%. The biggest part of Doximity's revenue is Subscription (94%); at Omnicell it is Connected devices, software licenses, and other (48%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Doximity and Omnicell compare in size?
Doximity has the larger market value: Doximity $5.12B and Omnicell $1.5B, at the last close.
Whose share price rose more over the last 12 months, DOCS or OMCL?
Over the last 12 months Doximity moved −38.1% and Omnicell −5.3%. Past price moves say nothing about the future.
Which has had more insider buying, Doximity or Omnicell?
Since 2006, Omnicell insiders reported 10 open-market purchases against 4 for Doximity. These are counts of what was filed, not a view on either stock.
Do members of Congress trade DOCS or OMCL?
In the last 12 months, members of Congress disclosed 1 trades in Doximity (DOCS) and 0 in Omnicell (OMCL).
When did insiders last buy DOCS and OMCL?
Doximity: May 27, 2022. Omnicell: Mar 18, 2025.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Doximity pageOmnicell pageRare insider trades this weekAll comparisons
https://oqro.io/compare/docs-vs-omcl

